White House Withdraws Heidi Overton’s FDA Nomination Amid Senate Opposition

 



Washington, November 18, 2026 — The White House has withdrawn Dr. Heidi Overton’s nomination to lead the U.S. Food and Drug Administration (FDA), following growing concerns that she lacked sufficient support among Senate Republicans to secure confirmation.

The decision came just hours before a scheduled vote by the Senate Health, Education, Labor and Pensions (HELP) Committee, ending Overton’s bid to become the next FDA commissioner and leaving the agency without a permanent leader.

Why Was Heidi Overton’s Nomination Withdrawn?

According to reports, the Trump administration decided to withdraw Overton’s nomination after uncertainty emerged over whether she could secure enough votes in the Senate.

Republicans held a narrow majority on the Senate committee responsible for reviewing her nomination. With Democrats expected to oppose her appointment, Overton needed strong support from Republican lawmakers to advance to a full Senate confirmation vote.

Several senators had expressed concerns about her positions on public health policies, including childhood vaccination recommendations, abortion-related medication and flavored electronic cigarettes.

Controversy Over Vaccine Policies

Overton faced scrutiny during her confirmation process over her support for proposals to reconsider the childhood vaccination schedule and separate combination vaccines, including the measles, mumps and rubella (MMR) vaccine.

Some lawmakers and medical organizations questioned whether her views could affect the FDA’s scientific independence and its approach to vaccine safety.

Her nomination became increasingly controversial as public health experts and senators debated the potential consequences of changes to established vaccination policies.

Concerns Over Abortion Medication

Overton’s views on abortion-related policies also contributed to opposition against her nomination.

She had previously criticized policies that expanded access to mifepristone, a medication commonly used for abortion and miscarriage management. The FDA regulates the drug, making the issue particularly important in the debate over who should lead the agency.

The administration's withdrawal of her nomination came amid ongoing political and legal discussions surrounding reproductive healthcare in the United States.

FDA Leadership Remains Uncertain

The withdrawal creates further uncertainty surrounding the leadership of the FDA, one of the country's most important public health agencies.

The FDA is responsible for regulating prescription drugs, vaccines, medical devices, food safety, tobacco products and other health-related products. Its decisions can have significant consequences for patients, healthcare providers, manufacturers and consumers.

Kyle Diamantas is currently serving as acting FDA commissioner while the administration considers its next steps.

Reports indicate that the White House may consider other candidates for the position, although no official replacement has been announced.

What Happens Next?

The Trump administration is expected to search for a new nominee who can gain sufficient support in the Senate.

The leadership transition comes at a challenging time for the FDA, which has faced policy disagreements, staffing changes and public debate over its regulatory priorities.

Overton’s withdrawal highlights the political challenges involved in appointing leaders to key federal health agencies and underscores the importance of Senate support in the confirmation process.

For now, the FDA will continue operating under acting leadership as Washington awaits the administration’s next decision regarding the agency’s permanent commissioner.

Source: Reuters, Associated Press and other news reports.

Disclaimer: This article is based on publicly available news reports and may be updated as additional information becomes available.


Next Post Previous Post
No Comment
Add Comment
comment url